Treatment of vemurafenib-resistant SKMEL-28 melanoma cells with paclitaxel

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Vemurafenib is a targeted therapy for BRAFV600E-mutated melanomas.
• Sole vemurafenib treatment often leads to melanoma recurrence due to resistance.
• Understanding resistance mechanisms is crucial for improving melanoma treatment outcomes.

Purpose of the Study:

• To investigate the molecular mechanisms of vemurafenib resistance in BRAFV600E melanoma cell lines.
• To evaluate the efficacy of paclitaxel as a potential combination therapy for resistant melanoma.
• To identify cell-type-specific resistance pathways to vemurafenib.

Main Methods:

• Establishment of three vemurafenib-resistant BRAFV600E melanoma cell lines (A375PR, A375MR, SKMEL-28R).
• Analysis of signaling pathway phosphorylation levels (RAS/RAF/MEK/ERK, AKT).
• Treatment of resistant cells with paclitaxel and AKT inhibitor (MK-2206) to assess effects on apoptosis, proliferation, and invasion.

Main Results:

• Vemurafenib-resistant cell lines exhibited reduced MEK and ERK phosphorylation.
• SKMEL-28R cells showed increased pAKT phosphorylation, a potential resistance marker.
• Paclitaxel treatment of SKMEL-28R cells decreased proliferation, invasion, and colony formation by reducing EGFR and pAKT levels.
• An AKT inhibitor (MK-2206) reduced vemurafenib-induced pAKTs in SKMEL-28R cells.

Conclusions:

• Melanoma cell-type influences the specific mechanisms of vemurafenib resistance.
• Paclitaxel demonstrates potential as an effective combination therapy with vemurafenib for treating resistant melanomas.
• Targeting the AKT pathway may overcome vemurafenib resistance in certain melanoma subtypes.